Sell Your Pharma Manufacturing Facility and Lease it BackContact Us >

PharmaBioSource Realty represented SHL Medical ( on the lease of its new U.S. medical device injection molding manufacturing facility in Charleston, SC.  The facility totals 270,000 SF of space and SHL is planning a $90M investment over the next 2 years.  Once operational in 2024, SHL will employ 165 staff to support its growing autoinjector device manufacturing demands.

SunCap – SHL Medical Palmetto Trade Center Announcement


PharmaBioSource Realty has sold Teligent’s injectable fill / finish and topical liquids and creams manufacturing and packaging facility to Leiters for $27M.

Marketing Flyer

Sever Pharma Solutions (SPS) acquired the assets of Foster Delivery Services (FDS) in Putnam, Connecticut.  The acquisition significantly expands SPS’s ability to leverage its expertise in the development of high-potent pharmaceutical products.

PharmaBioSource provided exclusive marketing and consulting services to sell AMRI’s small molecule API manufacturing operation located in Lodi, Italy. The Lodi operation known as Prime European Therapeutics S.p.A. (Euticals) was acquired by LIVIA Corporate Development, which specializes in acquiring European Corporate spin-offs/carve-outs. The Lodi site is specialized for the custom synthesis and manufacture of active pharmaceutical ingredients (APIs).

PharmaBioSource Realty provided exclusive real estate services to identify and negotiate the lease for the former Teva Chemical Synthesis Center in Malvern, PA located just outside of Philadelphia.  PharmaBioSource also provided start-up and logistics services to assist Flamma in occupying the 40,000 SF facility.

PharmaBioSource provided exclusive marketing and consulting services to sell AMRI’s sterile injectables manufacturing operation located in León, Spain. The León operation was acquired by Lyophilization Services of New England (LSNE), which will enable it to expand its reach into Europe. The León facility includes four high-speed, automated aseptic fill lines and commercial scale lyophilization for the manufacture of clinical and commercial drug products.

Bill Wiederseim, President & CEO of PharmaBioSource, Inc., meets with That’s Nice to discuss the importance of setting expectations for facility and M&A transactions in the CDMO sector to ensure a smooth and successful transaction process.

PharmaBioSource Realty provided exclusive marketing and real estate services to sell Shire’s biologics drug substance manufacturing site located in Milford, MA.  The Milford site was acquired by Rentschler Biopharma, which will utilize the site as its U.S. contract manufacturing and development headquarters.  The transaction included a supply agreement for Rentschler to manufacture Obizur through Shire’s proprietary roller bottle process.  In addition to the acquisition of the 93,000 SF facility, Rentschler will retain approximately 100 staff employed at the site.

PharmaBioSource exclusively represented Luitpold’s Osteohealth Division on the sale of GEM 21S® fully synthetic growth-factor enhanced matrix to treat periodontally related defects.  GEM 21S® utilizes innovative tissue engineering principles combining a highly purified bioactive protein, rhPDGF-BB, with an osteoconductive matrix, B-TCP.  GEM 21S® is a fully synthetic, sterile injectable grafting system designed to stimulate wound healing and bone regeneration.  PharmaBioSource managed the process to divest the GEM 21S® asset to potential buyers and investors, including target identification and marketing, data room development, due diligence oversight, negotiations and closing support.  The GEM 21S® asset was acquired by Lynch Biologics in September 2018.

MSD Animal Health, known as Merck Animal Health in the United States and Canada, today announced plans to purchase a new manufacturing facility in Krems an der Donau, Austria with the intention to expand its global vaccine manufacturing capacity. The facility, currently owned by Shire plc., was built in 2002 and will add to the company’s impressive global manufacturing capabilities.